Home / Business and Economy / Analysts Hail LivaNova as Top Undervalued UK Medtech Stock to Buy
Analysts Hail LivaNova as Top Undervalued UK Medtech Stock to Buy
4 Aug
Summary
- Jefferies analyst maintains Buy rating on LivaNova with $79 price target
- Strong growth potential driven by solid product cycle and market expansion
- Competitive edge in oxygenator market and Vagus Nerve Stimulation therapy
According to analysts, LivaNova PLC (NASDAQ:LIVN), a global medical technology company based in the UK, is one of the best undervalued stocks to buy currently. Jefferies analyst Matthew Taylor recently maintained a Buy rating on the company with a price target of $79.
The analyst is particularly optimistic about LivaNova's growth potential, driven by its solid product cycle. He noted the Essenz upgrade, which is expected to increase revenue through higher average selling prices as the replacement cycle advances. Additionally, Taylor is impressed by the company's expansion in the oxygenator market, where its increasing market share and production capacity give it a competitive edge over its peers.
Furthermore, the analyst points out LivaNova's progress in Vagus Nerve Stimulation therapy for drug-resistant epilepsy, which he believes strengthens the company's position in this treatment area. With strong long-term data supporting the therapy, LivaNova is well-positioned to capitalize on the growing demand for effective epilepsy treatments.
Overall, the article paints a positive picture of LivaNova's future, highlighting its innovative products, market expansion, and competitive advantages in the medical technology industry. Investors may find the company an attractive investment opportunity in the current market.
